226396-02-7Relevant articles and documents
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl Sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
Becker, Daniel P.,Barta, Thomas E.,Bedell, Louis J.,Boehm, Terri L.,Bond, Brian R.,Carroll, Jeffery,Carron, Chris P.,Decrescenzo, Gary A.,Easton, Alan M.,Freskos, John N.,Funckes-Shippy, Chris L.,Heron, Marcia,Hockerman, Susan,Howard, Carol Pearcy,Kiefer, James R.,Li, Madeleine H.,Mathis, Karl J.,McDonald, Joseph J.,Mehta, Pramod P.,Munie, Grace E.,Sunyer, Teresa,Swearingen, Craig A.,Villamil, Clara I.,Welsch, Dean,Williams, Jennifer M.,Yu, Ying,Yao, Jun
experimental part, p. 6653 - 6680 (2010/11/18)
α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMPs-2,-9, and-13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
-
, (2008/06/13)
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,
